SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma - Quaterly Results

11 Nov 2024 Evaluate
The company witnessed a 12.05% growth in the revenue at Rs. 2226.99 millions for the quarter ended September 2024 as compared to Rs. 1987.55 millions during the year-ago period.Net Profit recorded in the quarter ended September 2024 rise to 26.60% to Rs. 256.27  millions  compared to R. 202.42 millions in corresponding previous quarter.Operating profit surged to 375.48 millions from the corresponding previous quarter of 318.81 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 2226.99 1987.55 12.05 4671.05 3816.75 22.38 8193.68 6658.98 23.05
Other Income 79.63 81.82 -2.68 157.35 100.68 56.29 303.89 194.30 56.40
PBIDT 375.48 318.81 17.78 785.68 559.09 40.53 1410.70 1030.49 36.90
Interest 32.96 37.98 -13.22 67.69 93.43 -27.55 163.28 322.26 -49.33
PBDT 342.52 280.83 21.97 717.99 465.66 54.19 1247.42 1100.33 13.37
Depreciation 86.25 78.41 10.00 170.69 155.49 9.78 332.19 547.87 -39.37
PBT 256.27 202.42 26.60 547.30 310.17 76.45 915.23 552.46 65.66
TAX 0.00 0.00 0.00 0.00 0.00 0.00 -32.26 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 -32.26 0.00 0.00
PAT 256.27 202.42 26.60 547.30 310.17 76.45 947.49 552.46 71.50
Equity 507.19 507.19 0.00 507.19 507.19 0.00 507.19 408.16 24.26
PBIDTM(%) 16.86 16.04 5.11 16.82 14.65 14.83 17.22 15.48 11.25

Orchid Pharma Share Price

544.95 -14.25 (-2.55%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×